/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Alterity Therapeutics Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.49 0.0431(4.31%) ATHE at 04 Dec 2025 04:26 PM Biotechnology
Lowest Today 3.47
Highest Today 3.52
Today’s Open 3.52
Prev. Close 3.34
52 Week High 7.00
52 Week Low 1.90
Day’s Range: Low 3.47 High 3.52
52-Week Range: Low 1.90 High 7.00
1 day return -
1 Week return -9.09
1 month return -12.0
3 month return -34.39
6 month return -30.23
1 year return +75.53
3 year return -5.71
5 year return -77.39
10 year return -

Institutional Holdings

Point72 Asset Management, L.P. 0.86

Morgan Stanley - Brokerage Accounts 0.38

Greenleaf Trust 0.11

BNP Paribas Arbitrage, SA 0.05

Twin Lakes Capital Management, LLC 0.04

Fidelity Nasdaq Composite Index 0.01

Advisor Group Holdings, Inc. 0.00

Rhumbline Advisers 0.00

Ronald Blue Trust, Inc. 0.00

Coppell Advisory Solutions LLC 0.00

HB Wealth Management, LLC 0.00

JPMorgan Chase & Co 0.00

Northwestern Mutual Wealth Management Co 0.00

Steward Partners Investment Advisory, LLC 0.00

UBS Group AG 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 60.89 M

PB Ratio 2.1338

PE Ratio 0.0

Enterprise Value 37.59 M

Total Assets 46.03 M

Volume 21422

Company Financials

Annual Revenue FY25:5438918 5.4M, FY24:4019285 4.0M, FY23:0 0.0M, FY22:3537368 3.5M, FY21:3254048 3.3M

Annual Profit FY25:5311395 5.3M, FY24:3804981 3.8M, FY23:null 0.0M, FY22:3285598 3.3M, FY21:2984083 3.0M

Annual Net worth FY25:-12147828 -12.1M, FY24:-19123464 -19.1M, FY23:-13806515 -13.8M, FY22:-12847061 -12.8M, FY21:-15309353 -15.3M

Quarterly Revenue Q2/2025:3832993 3.8M, Q2/2024:2118561 2.1M, Q1/2024:690715 0.7M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Profit Q2/2025:3769068 3.8M, Q2/2024:2044949 2.0M, Q1/2024:652460 0.7M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Net worth Q2/2025:-4974493 -5.0M, Q2/2024:-12616281 -12.6M, Q1/2024:-4113288 -4.1M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Fund house & investment objective

Company Information Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.

Organisation Biotechnology

Employees 9

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow